All products / Type / Snap Pen
Retatrutide 10mg Snap Pen
Triple GLP-1/GIP/glucagon agonist — weight, glycaemic & metabolic research
SKU: SP-RET-10-2
99% Purity$290
- Format
- Snap Pen
- Dosage
- 0.1mg per click
- Capacity
- 10mg
Not available right now.
Sign in to savePotential benefits
- Weight-reduction research
- Glycaemic-control research
- Liver-fat & liver-health research
- Cardiometabolic-marker research
- Body-composition research
- Convenient Weekly Dosing
Retatrutide is an investigational peptide therapy designed to activate three critical metabolic receptors—GLP-1, GIP, and glucagon. This triple-agonist approach acts on the body’s metabolic signalling pathways, and has been studied for effects on fat loss, blood-sugar regulation, liver health, and inflammation.
A distinguishing feature of Retatrutide is its multi-hormone mechanism, which in research has been associated with appetite signalling, energy expenditure, reductions in visceral and liver fat, and changes in cardiometabolic markers. In clinical trials, Retatrutide showed among the highest weight-reduction results recorded in clinical research for a non-surgical agent, while also addressing underlying drivers of metabolic disease.
Retatrutide is a multi-receptor agonist, meaning it activates three hormone pathways simultaneously:
GLP-1 (Glucagon-like Peptide-1): Promotes satiety, slows gastric emptying, and enhances glucose-stimulated insulin secretion.
GIP (Glucose-dependent Insulinotropic Polypeptide): Enhances insulin release in response to meals and synergizes with GLP-1 to improve metabolic response.
Glucagon Receptor: Stimulates fat oxidation, increases energy expenditure, and reduces liver fat stores.
Together, these pathways have been studied for effects on energy balance, food intake, fat stores, and metabolic biomarkers relative to single-pathway agents.
A distinguishing feature of Retatrutide is its multi-hormone mechanism, which in research has been associated with appetite signalling, energy expenditure, reductions in visceral and liver fat, and changes in cardiometabolic markers. In clinical trials, Retatrutide showed among the highest weight-reduction results recorded in clinical research for a non-surgical agent, while also addressing underlying drivers of metabolic disease.
Retatrutide is a multi-receptor agonist, meaning it activates three hormone pathways simultaneously:
GLP-1 (Glucagon-like Peptide-1): Promotes satiety, slows gastric emptying, and enhances glucose-stimulated insulin secretion.
GIP (Glucose-dependent Insulinotropic Polypeptide): Enhances insulin release in response to meals and synergizes with GLP-1 to improve metabolic response.
Glucagon Receptor: Stimulates fat oxidation, increases energy expenditure, and reduces liver fat stores.
Together, these pathways have been studied for effects on energy balance, food intake, fat stores, and metabolic biomarkers relative to single-pathway agents.
- Participants in a 48‑week Phase 2 study lost up to 24.2% of initial body weight at higher doses.
- Significant reductions in HbA1c and fasting glucose were observed in adults with obesity ± type 2 diabetes, outperforming monotherapies.
- Over 80% of participants achieved ≥70% reduction in liver fat; >85% resolved steatosis in a MASLD subgroup.
- Notable drops in blood pressure, triglycerides (‑40%+), LDL, and inflammatory biomarkers.
- Retains lean mass while reducing fat mass, based on recent body‑composition data.
- Long half-life (~6 days) allows comfortable once‑weekly subcutaneous injections.
References
- Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
- Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial
- Research findings
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
| Molecular formula | C₂₂₁H₃₄₂N₄₆O₆₈ |
|---|---|
| Molecular weight | 4 Da |
| CAS number | 2381089-83-2 |
| Purity | 99% |
| Storage | Before reconstitution, store 6–50°C, refrigeration is not required. After reconstitution (mixing), keep refrigerated at 2–8°C at all times, use within 6 weeks. Do not freeze. Keep away from direct sunlight and heat. |
Sequence: Tyr-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-αMeLeu-Leu-Asp-Lys-Lys(diacid-C20-γGlu-AEEA)-Ala-Gln-Aib-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂
Synonyms: 2381089-83-2, EX-A7826E, GTPL13769
Research & background
Independent, research-focused reading. Educational references, not medical advice or product claims.
